secwatch.observer — SEC 8-K summary
======================================

Issuer:     bluebird bio, Inc. (—)
CIK:        0001293971
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001193125-23-297683
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bluebird bio enters $100M accounts receivable factoring agreement to accelerate cash collection
--------------------------------------------------------------------------------

- Up to $100M revolving factoring facility, 90% advance rate on receivables for LYFGENIA, ZYNTEGLO, SKYSONA.
- Fee: prime rate + 1.35% on funded amount plus 0.05% collateral monitoring fee; proceeds for working capital.
- 12-month initial term, renewable annually; early termination fee 2% (first year) or 0.75% thereafter.
- Purchaser assumes credit risk; seller must repurchase ineligible or disputed accounts.
- Bylaws amended to adopt universal proxy rules and enhance disclosure for stockholder nominations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293971/000119312523297683/0001193125-23-297683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293971/000119312523297683/d632206d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-297683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer